Endovascular treatment of primary M3 occlusion stroke in clinical practice: analysis of the German Stroke Registry

期刊论文
出版模式：

开放获取
发表日期：

2024年7月18日

查看全文

Niklas M. Beckonert,
Johannes M. Weller,
Anna C. Alegiani,
Tobias Boeckh-Behrens,
Milani Deb-Chatterji,
Gerhard F. Hamann,
Lars U. Krause,
Nils C. Lehnen,
Louisa Nitsch,
Sven Poli,
Christian Riedel,
Steffen Tiedt,
Sarah Zweynert,
Gabor C. Petzold,
Franziska Dorn,
Felix J. Bode,
J Berrouschot,
G Bohner,
J Borggrefe,
A Bormann,
M Braun,
B Eckert,
U Ernemann,
MS Ernst,
J Fiehler,
C Gerloff,
K Gröschel,
J Hattingen,
KH Henn,
F Keil,
L Kellert,
C Kraemer,
J Liman,
A Ludolph,
R Muehl-Benninghaus,
O Nikoubashman,
C Nolte,
M Petersen,
A Reich,
J Röther,
JH Schäfer,
M Schell,
P Schellinger,
E Siebert,
F Stögbauer,
G Thomalla,
C Trumm,
T Uphaus,
S Wunderlich

摘要

Background

Endovascular treatment (ET) options for acute stroke due to distal middle cerebral artery occlusions are rapidly evolving, but data on outcome and safety are sparse. We therefore performed an analysis of patients undergoing ET for primary M3 occlusions in routine clinical practice in a nationwide registry.

Methods

Patients enrolled between 01/20 and 12/21 in the prospective, multicenter German Stroke Registry-Endovascular Treatment (GSR-ET) were screened for mechanical thrombectomy performed for primary M3 occlusion. We analyzed neurological deficit as measured by the National Institute of Health Stroke Scale (NIHSS), symptomatic intracranial hemorrhage (sICH), thrombectomy technique, successful reperfusion (modified Thrombolysis in Cerebral Infarction [mTICI] score of 2b-3) and functional outcome as measured by the modified Rankin Scale (mRS) at discharge and 90 days.

Results

Out of 5574 patients, 11 patients (0.2%, median age 80 years, 54.5% female) underwent ET for primary M3 occlusion. All patients had pre-admission mRS ≤ 1, median NIHSS on admission was 8, and successful reperfusion was achieved in 6/11 patients (54.5%). While no vasospasm, dissection or perforation was reported, symptomatic intracranial hemorrhage occurred in 2 patients (18.2%). Favorable outcome (mRS ≤ 2) was achieved in 6/11 patients (54.5%) at 90-day follow-up.

Conclusions

ET for primary M3 occlusions is rarely performed. While technically feasible, the procedure’s potential benefits must be carefully weighed against its associated risks, including clinically relevant complications. Caution and further research is needed to optimize patient selection for this intervention.

Trial Registration

GSR-ET; ClinicalTrials.gov Identifier: NCT03356392; Trial Registration Date: 11/29/2017.